GLG News by Physicians who Treat Malignant Melanoma (US)
Articles with lock require a subscription to GLG News |
Request a free trial
March 31, 2008AN2728 phase 2a results encouraging.
Analysis of: Anacor Pharmaceuticals Announces Positive Results from Phase 2A Clinical Trial of AN2728 in Psoriasis Patients | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Anacor's recent release of the data from their phase 2a study of AN 2728 for psoriasis were encouraging. Over 69% actively treated plaques of psoriasis improved versus only 6% of placebo treated plaques. The study was limited by the short duration- only 28 days versus up to 16...
March 31, 2008Psoriasis associated with comorbidities- Is this to be expected?
Analysis of: Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions | www.pharmalive.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that it is one of the first to confirm what is a widely held belief among many dematologists who treat many patients with psoriasis. Specifically that these patients suffer a higher rate of cardiovascular diseases, depression, malignancy, etc. This makes perfect...
March 19, 2008Ustekinumab shows promise
Analysis of: Novel Biologic Agent Proves Highly Effective in Severe Plaque Psoriasis | www.medscape.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Centocors new product- Ustekinumab /CNTO 1275 had impressive results in the recent PHOENIX trials and the application is under review at the FDA. The PASI score reductions are superior to the exiting agents such as Enbrel and Humira, and are comparable to those of the other Centocor product- Remicade...
March 7, 2008Renovo's Juvista product holds promose
Analysis of: Juvista Phase II Trial Results in Scar Revision and Breast Augmentation Surgery | www.renovo.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This article is important in that this is an under served market. Current scar reduction products are only modestly effective, or not effective at all. An agent which has a "70% "reported reduction in scar appearance,is safe, and only has to be used a few times has a large market and will be successful....
March 6, 2008Phosphagenics Topical Retinoic Acid Clinical Trial Initiated
Analysis of: Phosphagenics Initiates US Clinical Trials For Its Topical Retinoic Acid | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
This new delivery system from Phosphagenics for enhancing absorption and reducing irritation will have moderate effect on the retinoid market. Retinoic Acid use has been in decline not so much because of irritation, but because of the introduction of more efficacious retinoids like Tazorac and Differin...
February 25, 2008FDA Correctly Approves Avastin for Breast Cancer Based on PFS Advantage
Analysis of: Genentech Clears Hurdle On Cancer Drug Avastin | online.wsj.com
Author: Eric Whitman, Medical Director, Office of Grants and Research, Atlantic Health System Inc
FDA approval of Avastin in the treatment of advanced breast cancer will have an effect on the sales of the drug, but it is not clear to me how significant that effect will be, since it is already approved in Europe and has been widely used off-label for USA breast cancer patients already.
I am glad...
February 20, 2008More misleading Provenge data from Dendreon
Analysis of: Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com
Author: Eric Whitman, Medical Director, Office of Grants and Research, Atlantic Health System Inc
This data attempts, yet again, to suggest that Provenge is more effective when the cell counts are higher, and more of the cells have CD54 "helper" antigens on their surface. These data are similar to other misleading news releases about Provenge from Dendreon. This is a subset of patients from...
February 19, 2008Avastin In Breast cancer
Analysis of: In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com
Author: Taral Patel, Oncologist, Mid Ohio Oncology Hematology Inc.
New data with low and high dose of Avastin with Taxoter
February 19, 2008improve Overall survival in prostate cancer
Analysis of: Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com
Author: Taral Patel, Oncologist, Mid Ohio Oncology Hematology Inc.
esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...
February 13, 2008
Fears of safety and fears of a black box warning.
Analysis of: FDA Issues Warning About Botox Deaths | www.pharmalot.com
Author: GLG Expert Contributor
Fears of safety and fears of a black box warning.Analysis of: FDA Issues Warning About Botox Deaths | www.pharmalot.com
Author: GLG Expert Contributor
Is Botox as safe as we have imagined it to be? The implications of an impending possible black box warning on the cosmetic and medical use of Botox in dermatology.
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 159
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008